NCT01013753 - A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Asthma

Interventions

DRUG

Placebo

Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler

DRUG

Olodaterol (BI 1744) high

Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat

DRUG

Olodaterol (BI 1744) medium

Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat

DRUG

Olodaterol (BI 1744) very low

Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat

DRUG

Formoterol 12 mcg

Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups

DRUG

Olodaterol (BI 1744) low

Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat

Trial Locations (27)

Unknown

1222.27.43002 Boehringer Ingelheim Investigational Site, Linz

1222.27.43004 Boehringer Ingelheim Investigational Site, Schlüsslberg

1222.27.43001 Boehringer Ingelheim Investigational Site, Thalheim bei Wels

1222.27.43003 Boehringer Ingelheim Investigational Site, Vienna

1222.27.49003 Boehringer Ingelheim Investigational Site, Berlin

1222.27.49004 Boehringer Ingelheim Investigational Site, Berlin

1222.27.49009 Boehringer Ingelheim Investigational Site, Berlin

1222.27.49011 Boehringer Ingelheim Investigational Site, Frankfurt

1222.27.49008 Boehringer Ingelheim Investigational Site, Hanover

1222.27.49002 Boehringer Ingelheim Investigational Site, Lübeck

1222.27.49007 Boehringer Ingelheim Investigational Site, Rüdersdorf

1222.27.49006 Boehringer Ingelheim Investigational Site, Wiesbaden

1222.27.49010 Boehringer Ingelheim Investigational Site, Wiesloch

1222.27.48001 Boehringer Ingelheim Investigational Site, Lodz

1222.27.48002 Boehringer Ingelheim Investigational Site, Lodz

1222.27.48003 Boehringer Ingelheim Investigational Site, Poznan

1222.27.48004 Boehringer Ingelheim Investigational Site, Proszowice

1222.27.40002 Boehringer Ingelheim Investigational Site, Bucharest

1222.27.40003 Boehringer Ingelheim Investigational Site, Bucharest

1222.27.42101 Boehringer Ingelheim Investigational Site, Bardejov

1222.27.42103 Boehringer Ingelheim Investigational Site, Lučenec

1222.27.42104 Boehringer Ingelheim Investigational Site, Martin

1222.27.42102 Boehringer Ingelheim Investigational Site, Spišská Nová Ves

1222.27.38601 Boehringer Ingelheim Investigational Site, Golnik

1222.27.38605 Boehringer Ingelheim Investigational Site, Kamnik

1222.27.38604 Boehringer Ingelheim Investigational Site, Topolšica

1222.27.38603 Boehringer Ingelheim Investigational Site, Zgornje Hoče